Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM1811-03 in Advanced Tumors
NCT05781386Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suvicitumab in solid tumor (advanced stage) and cutaneous T-cell lymphoma (CTCL), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose or Recommended Dose at 28 days, Objective Response Rate for Solid Tumors up to 1 year and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
suvicitumab
03
Conditions
solid tumor (advanced stage)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT05781386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781386.